Module

Hepatitis JournalOptions – September/October 2005

CME Program Director: Robert G. Gish, MD, David L. Thomas, MD, MPH

Faculty:

Hal B. Jenson, MD, MBA Emmet B. Keeffe, MD, MACP Daryl T-Y Lau, MD, MSc, MPH, FRCP(C)

Paul Martin, MD Philip Rosenthal, MD Richard K. Sterling, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

• Describe the results of recent studies of diagnostic tests for viral hepatitis and its complications, including fibrosis, cirrhosis, and hepatocellular carcinoma.
• Review the epidemiology, pathogenesis, and natural history of hepatitis.
• Discuss the latest treatments, both approved and experimental, for hepatitis and its complications.

Topics covered include:

• Isolated Portal Fibrosis: Extending the Histologic Spectrum of NASH
• The Unnatural History of NASH
• Epoetin alfa: A Difference-maker in the Fight Against HCV?
• Sexual Transmission of HCV Among MSM
• Is It Likely That TIPS Could Cause Hepatocellular Carcinoma?
• For NASH, Does the Treatment Matter?
• A Viable in Vitro Cell Model for HCV Replication
• A New Serum Marker for Fibrosis: Glycoproteins
• Peginterferon Beats Standard Interferon, Again
• The Next Generation of Diagnostics to Measure Fibrosis
• To Break the Chain: HBV Vaccination for Incarcerated Populations
• To Break the Chain: HBV Vaccination for Incarcerated Populations
• Success of Universal Childhood HBV Vaccination
• Treating Chronic Hepatitis B with Peginterferon Alone or with Lamivudine
• Hepatitis B Genotypes in Hepatocellular Carcinoma
• Risk of Hepatocellular Carcinoma Associated With Serum HBV DVA Level
• Pegylated Interferon and Ribavirin: Also the Standard of Care for HIV-infected Persons with Hepatitis C
• Alternative Medicine: Clinical Trials Needed
• Consensus Interferon Plus Ribavirin for Treatment of HCV Nonresponders
• The Incarceration Connection: HBV Outbreaks and Interventions
• Modeling How Ribavirin Works: Esoteric, Yet Vital
• HCV: Another Virus Associated With Lymphoma
• Ascertaining the Natural History of Vertically Acquired HCV Infection in Children
• Treating Patients With Advanced HCV Infection Awaiting Transplantation
• Getting Lean to Prevent Fibrosis Progression
• Natural History of NASH: More Questions Than Answers
• Ribavirin and Didanosine: An Unhealthy Combination?
• Neuropsychiatric Symptoms, Whatever the Cause, Must Be Managed
• HCV in the California Correctional System
• Antiretroviral Therapy and HCV-HIV Coinfection: How Safe?
• Is Liver Transplantation from Living Donors More Risky Than From Deceased Donors?
• Immunomodulation Still Promising for HCV Treatment
• Treating HCV-Infected Children With Interferon and Ribavirin
• Commentary
• Beta-blockers Do Not Prevent Development of Varices in Patients With Cirrhosis
• Long-Term Use of Adefovir Dipivoxil to Treat HBeAg-Negative Chronic Hepatitis B
• Highlighting Missed Opportunities for Adult HBV Vaccination
• The Mysteries of HCV Genotype
• Does Tetanus Toxoid Prevent Multiple Sclerosis?
• Ascites Returns to the Spotlight
• Exercise May Be Key to Treating NASH
• Use of Ribavirin for Hepatitis C Virus-Related Renal Disease
• Treating HBeAg-positive Chronic Hepatitis B with Pegylated Interferon and Lamivudine
• Race Matters
• The Endocannabinoid CB2 Receptor: Hepatic Fibrosis Goes up in Smoke?
• Hepatic Iron Overload Negatively Affects Posttransplantation Survival
• HIV Coinfected Patients Have Similar Progression of HCV Liver Disease
• Questions Remain After Phase IIb Trial of Telbivudine vs Lamivudine for Chronic Hepatitis B
• Commentary
• Acetaminophen-Induced Acute Liver Failure in the United States
• Comparing Peginterferon and Lamivudine in Treating HBeAg-Positive Chronic Hepatitis B
• Assessing High-Dose Ribavirin for HCV Genotype 1
• Neutralizing HCV
• RFA: A Sturdy Bridge to Liver Transplantation
• HCV Transmission in an Outpatient Clinic: Lessons for Clinic Oversight
• Twelve Weeks of Therapy Can Be Sufficient for HCV Genotypes 2 & 3
• Prolonged Inhibition of Serum HBV DNA After Discontinuation of Clevudine: Key to Greater Antiviral Efficacy or Impaired Safety?
• Treatment of HBeAg-negative chronic hepatitis B: is peginterferon monotherapy the treatment of choice?
• BCLC Most Predictive of 7 HCC Staging Systems in Head-to-Head Comparison
• Golgi Glycoprotein (GP73) as a Serum Marker for HCC
• Hormone Replacement Therapy and Fibrosis Progression in HCV-infected Women
• Risk Factors for the Perinatal Transmission of HCV
• HCV Infection Alone Has Little Impact on Brain Function
• HBV Vaccination Gets a Boost
• Screening for HCC: More Promises
• Race Matters
• The Good and Bad of Modeling
• Advancing the Case for Noninvasive Serum Markers of Liver Fibrosis
• Minute Amounts of Residual HCV RNA Should Not Deter Antiviral Therapy
• Epoetin alfa: Improving Quality of Life with HCV Treatment
• Total HCV core antigen quantification: an alternative to HCV RNA measurements?
• Liver Transplantation in 5 HIV-Coinfected Patients
• What Defines Cure for HCV Infection?
• Depression and Treating Hepatitis C
• Coffee, Tea Consumption Associated With Lower Incidence of Chronic Liver Disease
• Hepatic Iron Concentration and Combination Therapy for Hepatitis C
• Good News for Patients with Refractory Ascites
• How Much Is Enough: Does One Size Really Fit All HCV Genotype 1 Patients?
• Alpha-Fetoprotein as a Predictor of Recovery from Acetaminophen-Induced Toxicity
• Myth and Future Directions in Treating Hepatic Encephalopat
• Hepatitis B Looming Larger in HIV-infected Patients
• Modeling Viral Kinetics in HCV and HIV/HCV Patients
• The Failure to Vaccinate Patients with Chronic Hepatitis C Against HAV
• Interferon Reduces HCV-associated HCC and Improves Survival
• Better Tests, Safer Blood
• Lamivudine Resistance + Entecavir Substitutions = Clinical Entecavir Resistance
• Can You Have Your Vaccine and Eat it, too?
• Do We Need New Drugs Effective Against All HCV Genotypes?
• Pegylated Interferon and Ribavirin: Also the Standard of Care for HIV-infected Persons with Hepatitis C
• Treating Anemia During Interferon/Ribavirin Therapy
• Matching Transplant Results to Public Policy
• Total HCV core antigen quantification: an alternative to HCV RNA measurements?
• Promise of Tenofovir for Hepatitis B
• More Evidence That HCV Is Not Transmitted Sexually
• Finding Reliable Indices of Treatment Response in Autoimmune Hepatitis
• The Impact of Differing Vaccination Strategies for Hepatitis A in the United States and Israel
• Can Suppressed cccDNA Mean Cure?
• Ocular Side Effects from Interferon: What Do You Do Now?
• Hepatitis A Incidence and Mortality in California
• Grappling With HCV Mortality Data
• Synergistic Risk Factors for HCC
• Determining Who To Treat Without Biopsy
• Continuous Circular Conversations on Covalently Closed Circular (ccc) DNA in HBV Therapy: Are We Getting Closer?
• 24 Weeks of Peginterferon + Ribavirin Sufficient for HCV Genotypes 2 & 3
• Better Tests, Safer Blood